NeuralInk

Executive Summary

Neuralink is a neurotechnology company developing implantable brain-computer interfaces (BCIs) to treat severe neurological conditions and ultimately enhance human cognition. Founded in 2016, the company has pioneered high-bandwidth neural implants capable of reading and writing neural signals. Neuralink's technology has progressed from animal studies to human clinical trials, with its first-in-human device implant in 2024. The company aims to restore autonomy to patients with paralysis, blindness, and other neurological disorders through bidirectional communication with external devices. Neuralink's long-term vision includes enabling symbiosis with artificial intelligence, expanding human capabilities beyond natural limits.

Upcoming Catalysts (preview)

• Q3 2026First human clinical trial results (PRIME study)80% success
• Q4 2026FDA breakthrough device designation for next-gen implant70% success
• H1 2027Strategic partnership with major hospital network for expanded trials60% success